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Abstract 
 
Cancer stem-like cells (CSCs) are rare subpopulations of cells that are drug resistant and have 
been shown to be responsible for the recurrence of cancer. CSCs are typically not responsive to 
traditional cancer treatments, so an alternative method, able to overcome the drug resistance of 
these subpopulations, is desirable. Nanoparticles are one potential solution to this problem and 
are currently under intense research. The aim of this study was to determine an ideal method (i.e. 
cheap, quick, and efficient) for synthesizing and loading nanoparticles with therapeutics for 
treating cancerous cells. A novel nanoprecipitation method was designed to create smaller and 
more homogeneous particles compared to the traditional nanoprecipitation method. We 
hypothesized that this method would be able to encapsulate therapeutic agents in Pluronic F127 
and poly(L-lactic-co-glycolic acid) that would result in nanoparticles, further coated with 
triphenylphosphonium and hyaluronic acid for targeting capabilities, less than 200nm in diameter 
with surface charges below -20mV. Further, we hypothesized this method would result in higher 
encapsulation efficiencies of therapeutics and be able to target mitochondria in vitro. It was 
found that infusion rates of 20ml/hr for water and 4ml/hr for oil, a polymer concentration of 
10mg/ml, and a 1:1 ratio of PLGA to PF127-TPP resulted in the smallest (168.48±6.3nm), most 
homogeneous nanoparticles (PDI = 0.05) with surface charges of -35.54±3mV. The 
encapsulation efficiency for porphyrin was 73.5±3.4%, but was lower for lonidamine and 
doxorubicin, at 36.3±5.2% and 21.9±15.1%, respectively. Mitochondrial targeting capabilities of 
the particles were confirmed with PLGA-PF127-TPP-Dox nanoparticles with MDA-MB-231 
cells via confocal images and fluorescence overlap of doxorubicin with MitoTracker Deep Red 
dye. These results indicate that while more studies need to be done to determine drug release 
mechanisms and kinetics and targeting capabilities of PLGA-PF127-TPP-HA nanoparticles, the 
novel method described here is viable for creating dual targeting nanoparticles capable of 
treating drug resistant phenotypes of CSCs. 
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Chapter 1: Introduction 
 
1.1 Background 
Within the field of cancer, cancer stem-like cells (CSCs) have attracted much attention in 
recent years. CSCs are capable of self-renewal to maintain stemness, as well as differentiating 
into all types of residual cells associated with the original tumor. Additionally, a drug resistant 
phenotype tends to arise across most CSC populations. These phenotypes arise either due to an 
overexpression of drug efflux pumps in the cell or maintenance of a somewhat dormant state in 
which the cells metabolize substances much slower than the surrounding tumor. As such, 
evidence has shown that these types of cells are partially responsible for tumor recurrence1,2,3.  
A method for treating cancer that has seen huge strides since its inception is the use of 
therapeutic nanoparticles. There are several advantages to using nanoparticles as opposed to 
traditional chemotherapy. First, nanoparticles have small, tunable sizes. The rapid growth of 
tumors causes them to have a leaky vasculature compared to normal tissue, and this gives rise to 
what is known as the enhanced permeability and retention (EPR) effect. Pores in tumor 
vasculature are larger than they are for normal tissue, ranging from ~20-250nm. Nanoparticles in 
this size range can leak into tumor tissue but not normal tissue, thus taking advantage of the EPR 
effect. Another benefit to using nanoparticles is that they can encapsulate and deliver a wide 
variety of therapeutic agents. Not only can they encapsulate normal therapeutic drugs for 
effective in vivo delivery4, but they can also encapsulate combinations of drugs and RNA to 
reverse drug resistance in cancer cells5. Finally, nanoparticles can be modified to target cancer 
cells beyond the EPR effect. By modifying the surfaces of nanoparticles with ligands for cell 
surface receptors that are overexpressed in the cancer cell line of interest, they effectively 
become highly targeted and more efficient at delivering their payloads to the intended cells4,6. A 
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common modification is the addition of hyaluronic acid (HA) onto the surface of nanoparticles. 
This is because HA is a ligand for the CD44 cell surface receptor that is overexpressed in many 
types of cancers and CSCs, and has been shown to be effective at targeting tumors in vivo7. 
Besides being able to target at the cellular level, nanoparticles can also target at the 
organelle level. One molecule of interest here was triphenyphosphonium (TPP), which is capable 
of targeting and binding to mitochondria. TPP is a lipophilic cation that takes advantage of the 
strong negative membrane potential of mitochondria to bind and internalize in the mitochondrial 
matrix. Marrache et al. have shown that nanoparticles modified with TPP on their surfaces are 
capable of targeting mitochondria in vitro8. Mitochondria have become attractive targets for anti-
cancer drugs. The reasons for this are two-fold: first, mitochondria are crucial for cell survival as 
they are responsible for most of the ATP production within cells and thus provide most of the 
energy needed for cellular processes; second, it has been found that mitochondria are crucial 
regulators of apoptotic pathways due to their regulation of the translocation of pro-apoptotic 
proteins from the mitochondrial intermembrane space to the cytosol9. One of the most prolific 
phenotypes across all cancer cell lines is characterized by suppressed apoptotic pathways, 
therefore mitochondria-directed delivery of drugs that are designed to trigger apoptosis would 
provide a promising strategy for treating cancer.  
One of the most common methods used to synthesize nanoparticles is nanoprecipitation. 
In this method, an organic phase consisting of the desired polymers and drugs – dissolved in 
organic solvents – is added dropwise to de-ionized water while stirring. Three important aspects 
here are that the organic solvents be mostly immiscible in water, the polymers used are 
amphiphilic, and the intended payloads are hydrophobic. If these conditions are met, then when 
the organic phase is added to the water phase, the polymer blocks will self assemble and trap the 
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payload in their core. The organic solvents are then evaporated out, and the nanoparticle 
solutions can be washed and collected. To achieve nanoparticles with higher encapsulation 
efficiencies, slower drug release, and lower polydispersity, several groups of researchers have 
used microfluidics approaches with co-axial, focused streams in either a 2D10 or 3D manner11. 
1.2 Motivation 
 The motivation for this study arises from a few areas. First, as mentioned before, CSCs 
are often unaffected by traditional chemotherapies and are linked to the recurrence of tumors. 
Thus, it is desirable to find a method that is capable of eradicating CSC populations along with 
the rest of the tumor. One method that has shown promise in this area is mitochondrial targeting 
of cancer cells. Nanoparticles that are coated with mitochondrial targeting moieties are 
particularly effective at delivering their payloads to cancer cells and have the potential to 
overcome any drug resistant phenotypes that may be present in the cancer cell populations being 
treated, including CSCs. Finally, while nanoprecipitation methods are viable for synthesizing 
nanoparticles, there is room for improvement in several areas. Microfluidics approaches attempt 
to solve these problems, but they may get overly complicated or expensive. Finding a cheap, 
easy to set up and use alternative to microfluidics nanoprecipitation that still retains the benefits 
would be an important step in nanoparticle research.  
1.3 Significance 
 The significance of this study relates directly to cancer and its burden on humans. 
According to the World Health Organization, cancer is the second leading cause of death 
globally and was responsible for 8.8 million deaths in 2015. Just in the United States alone, an 
estimated 1.7 million new cases of cancer were diagnosed in 201712. Not only is there a burden 
on human life, but cancer is also a large economic strain. National expenditures for cancer care 
totaled nearly $125 billion in 201011. From these statistics, it is evident that cancer will continue 
4 
 
to be a problem both economically and in terms of human death, unless cheaper, more effective 
methods of treatment that mitigate the chances for relapse are pursued. 
1.4 Specific Aims 
 Aim 1: Prepare a biodegradable and biocompatible, multifunctional, nanoscale drug 
delivery system via a novel nanoprecipitation method capable of selectively targeting 
mitochondria. We hypothesize that using a novel nanoprecipitation method to encapsulate 
therapeutic agents in Pluronic F127 and poly(L-lactic-co-glycolic acid) will result in 
nanoparticles, further coated with triphenylphosphonium and hyaluronic acid, less than 200nm 
in diameter with surface charges below -20mV. 
Aim 2: Evaluate the drug encapsulation efficiency and mitochondrial immobilizing 
capabilities of the drug delivery system in vitro. We hypothesize that this method will result in 
higher encapsulation efficiencies compared to traditional nanoprecipitation and particles and 
their payloads will be able to selectively target mitochondria. 
Chapter 2: Methods 
 
2.1 Preparation of compounds 
 Prior to any nanoparticle synthesis, several compounds had to be prepared. The chemical 
synthesis and modification techniques used were outside the scope of this study, but are worth 
noting to avoid confusion. Please direct all inquiries in the matter to Dr. Jianghsheng Xu, 
postdoctoral researcher in Dr. He’s lab. The encapsulated drug that was used for most of this 
study was a derivative of porphyrin, modified to have a benzyl chloride group (Ps-Cl), which 
was previously shown to be mitochondrial targeting13. TPP was also synthesized prior to the start 
of this study. Additionally, Pluronic F127 (PF127) modified with TPP (PF127-TPP) had to be 
prepared prior to nanoparticle synthesis.  
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2.2 Nanoparticle synthesis 
 Nanoparticles were synthesized using a somewhat novel nanoprecipitation method 
(Error! Reference source not found.). A double lumen needle, typically used for 
electrospinning, was used to create co-axial streams of the two liquid phases. Inlet 1 was the 
organic phase and the inner stream while Inlet 2 was the water phase and outer stream. Since this 
was a somewhat novel method, we wanted to explore various conditions to find optimal ones.  
 
Initially, different concentrations of PF127 (without TPP modification) were dissolved in 
the oil phase. For each condition, the concentration of Ps-Cl was kept the same at 2mg/ml and 
the total volume of the organic phase was kept the same at 2ml. Ps-Cl was dissolved in 
tetrahydrofuran (THF) and PF127 was dissolved in acetonitrile (ACN). To have 2ml of the 
organic phase (sometimes referred to as oil), 2mg of Ps-Cl was dissolved in 1ml THF and added 
Figure 1: Schematic of novel nanoprecipitation method used. Inlet 1 was connected directly to the syringe containing the organic 
phase, while Inlet 2 was connected via Tygon tubing to the syringe containing water. Tygon tubing was also used to connect the 
needle to the flask. It was made sure that the end of the tube was underneath the surface of the fluid in the flask. Upon reaching 
the outlet of the needle, the two phases underwent mixing, and the amphiphilic polymers self assembled trapping the 
hydrophobic Ps-Cl in their core. 
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to either 20, 40, or 100mg PF127 dissolved in 1ml ACN (for 10, 20, or 50mg/ml, respectively). 
This way, the drug to oil ratio was kept the same throughout each condition. De-ionized (DI) 
water was used and kept at a ratio of 10:1 (v:v) to oil. The total volume of water was split 
equally between a syringe and a round bottom flask, with 10ml in each. Using syringe pumps, 
water was infused into the flask at a rate of 10ml/hr and the organic phase was infused at a rate 
of 2ml/hr. Since Ps-Cl is light sensitive, the nanoparticle synthesis process was protected from 
light as much as possible. After both phases had been completely infused, the mixture was 
allowed to stir for an additional hour. Following this, the solution was centrifuged at 13600 G for 
10 minutes to collect the nanoparticles and the supernatant was removed. Nanoparticles were 
washed with DI water twice before final collection. Higher infusion rates were also tested with 
all three concentrations of PF127. They were 20ml/hr and 4ml/hr for the water and oil phases, 
respectively.  
Once it had been determined what polymer concentrations and infusion rates resulted in 
the smallest and most homogeneous nanoparticle populations, poly(L,lactic-co-glycolic acid) 
(PLGA) was added to the organic phase. At this point, we also began using PF127-TPP. The 
ratio of PLGA to PF127-TPP was varied to find optimal conditions. The conditions tested were 
1:1, 1:3, and 1:1.5 (PLGA:PF127-TPP). Both polymers were dissolved together in ACN. Again, 
the water to oil ratio was kept constant at 10:1 (v:v), and the Ps-Cl concentration was kept 
constant at 2mg/ml. Total volumes used were 20ml DI water (10ml in the syringe and 10ml in 
the flask) and 2ml organic phase. Using the optimal polymer concentration and infusion rates, 
nanoparticles were synthesized and allowed to mix for an additional hour after infusion had 
ceased. The same process for nanoparticle collection that was outlined above was used here as 
well. 
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2.3 Hyaluronic acid modification 
 After nanoparticles had been synthesized with PLGA, PF127-TPP, and PS-Cl (PPP-T), 
they were further modified with HA. Briefly, 1mg of PPP-T nanoparticles were dispersed in 5ml 
DI water. Additionally, 3mg HA was dissolved in 1ml DI water. The nanoparticle solution was 
put under magnetic stirring and the HA solution was added dropwise. After HA addition, the 
mixture was allowed to mix for 4 hours under a closed atmosphere. The entire solution was 
centrifuged at 13600 G for 10 minutes, the supernatant was poured off, and the particles were 
washed with DI water before final collection. 
2.4 Nanoparticle characterization 
 Nanoparticle size and surface potential were analyzed using a Brookhaven (Holtsville, 
NY) 90 Plus/BI-MAS dynamic light scattering (DLS) instrument by dispersing nanoparticles 
(500µg/ml) in DI water. Nanoparticle size and morphology was also characterized using 
transmission electron microscopy (TEM). Nanoparticles were examined after being negatively 
stained with uranyl acetate solution (2% w/w) using an FEI (Moorestown, NJ) Tecnai G2 Spirit 
transmission electron microscope. 
2.5 Drug encapsulation efficiency 
 Once the optimal conditions for nanoparticle synthesis had been determined (i.e. which 
conditions resulted in the smallest, most homogeneous particles), the encapsulation efficiency of 
Ps-Cl was analyzed. The amount of Ps-Cl encapsulated was determined spectrophotometrically 
using a Beckman Coulter (Indianapolis, IN) DU 800 UV-Vis spectrophotometer based on its 
absorbance at 405mn. The amount of Ps-Cl not encapsulated (free Ps-Cl) was determined by 
taking 200µl of the supernatant liquid after centrifuging a nanoparticle solution and adding it to 
2ml of DI water. The absorbance of this was compared to 200µl of the nanoparticle solution 
before centrifugation in 2ml DI water (PPP-T NPs + free Ps-Cl). Empty nanoparticles were also 
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made and their absorbance was measured to determine the contribution of particles to the PPP-T 
NPs + free Ps-Cl solution. The encapsulation efficiency was calculated using the following 
equation: 
𝐸𝐸 =  
𝐴𝑃𝑃𝑃−𝑇 −  𝐴𝐸𝑚𝑝𝑡𝑦
𝐴𝑃𝑃𝑃−𝑇 −  𝐴𝐸𝑚𝑝𝑡𝑦 +  𝐴𝑃𝑠−𝐶𝑙
 
where APPP-T is the absorbance of PPP-T nanoparticles and un-encapsulated Ps-Cl, AEmpty is the 
absorbance of empty PLGA-PF127-TPP nanoparticles, and APs-Cl is the absorbance of free Ps-Cl. 
All absorbance values were taken at 405nm.  
2.6 Encapsulating different drugs 
 In addition to encapsulating Ps-Cl using this nanoprecipitation method, we also wanted to 
show that it would be viable for other, less hydrophobic drugs. To test this, we used two common 
cancer drugs, lonidamine (Lon) and doxorubicin (Dox). Nanoparticles were synthesized using 
the previously determined optimal conditions, except with 2mg/ml Lon (PPL-T) or Dox (PPD-T) 
instead of Ps-Cl. Lonidamine was dissolved in THF. The stock Dox product available was a 
hydrochloride salt, making it soluble in water and not ideal for nanoprecipitation. Thus, we 
dissolved Dox in 2ml methanol and added 5µl triethylamine (TEA) to obtain free Dox, which is 
more hydrophobic. Barring this exception, the same protocol outlined above was used for 
synthesis, collection, characterization, and determination of encapsulation efficiency for these 
nanoparticles. Nanoparticles encapsulating Lon and Dox did not undergo HA modification at any 
point.  
2.7 Determination of mitochondrial targeting 
 PPD-T nanoparticles were used to determine the mitochondrial targeting capabilities of 
nanoparticles with TPP modification in vitro. MDA-MB-231 human breast cancer cells (ATCC, 
Manassas, VA) were cultured in DMEM supplemented with 10% FBS and 1% Pen Strep at 37°C 
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in a humidified 5% CO2 incubator. Media was changed every other day. Once cells had reached 
at least 70% confluency, they were passaged and seeded into individual 35mm dishes with cover 
glasses at 2x105 cells/dish and incubated for an additional 24 hours. Then, the media was 
replaced with 2ml of either free Dox at 5µg/ml DMEM, PPD nanoparticles at 60µg/ml DMEM, 
or PPD-T nanoparticles at 60µg/ml DMEM. After incubation for 4 hours, that media was 
removed and cells were stained with DAPI and MitoTracker Deep Red FM dyes and then fixed. 
Cover glasses were mounted onto glass slides with anti-fade mounting medium (Vector 
Laboratories Burlingame, CA) for examination using an Olympus FluoView™ FV1000 confocal 
microscope. 
Chapter 3: Results and Discussion 
 
3.1 Determination of optimal conditions 
 As seen in Figure 2a, the optimal conditions in regards to polymer concentration and 
infusion rates as determined by DLS were 10mg/ml for the polymer concentration, 20ml/hr for 
the water infusion rate, and 4ml/hr for the oil infusion rate. These conditions created 
nanoparticles that were 50.49±11.9nm in diameter, with a polydispersity (PDI) of 0.225. Using a 
smaller polymer concentration and faster infusion rates ultimately allowed for less contact time 
between less materials. The fact that there were less materials in the organic phase and less time 
for them to be in contact with each other in a uniform fashion (before being expelled from the 
tube into the flask) can account for the smaller, more homogeneous nanoparticles that resulted. 
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There was less of a chance for the amphiphilic polymer molecules to interact with each other – 
and less polymer molecules to interact overall – to form larger aggregates. Thus, only small 
nanoparticles, all approximately the same size, resulted from a polymer concentration of 
10mg/ml and infusion rates of 20ml/hr for water and 4ml/hr for oil.  
Additionally, it was found that using a PLGA to PF127-TPP ratio of 1:1 was ideal 
(Figure 2b). Using all of these conditions together created by far the most homogeneous 
b) 
c) 
Figure 2: Size distribution of 
nanoparticles synthesized under various 
conditions. a) DLS showing that faster 
infusion rates and a polymer 
concentration of 10mg/ml resulted in the 
smallest, most homogeneous 
nanoparticles. b) DLS showing that 
when using faster infusion rates and a 
polymer concentration of 10mg/ml, a 1:1 
ratio of PLGA to PF127-TPP resulted in 
the smallest, most homogeneous 
nanoparticles. c) TEM images showing 
PPP-T nanoparticles created under 
optimal conditions as having a uniform 
size about 100nm in diameter. 
a) 
11 
 
population of nanoparticles that was seen in this study with a polydispersity of 0.05. PLGA is 
much more hydrophobic than just PF127, which would account for the extremely low PDI. 
Figure 2c shows a TEM image of PPP-T nanoparticles having a very uniform size distribution. 
Although TEM images showed these nanoparticles to be about 100nm in size, DLS 
measurements gave a value of 168.48±6.3nm. This difference between TEM and DLS is typical, 
as the value given from DLS can be heavily swayed by only a few larger particles, skewing the 
result to a larger value. PPP-T nanoparticles were larger than those with just PF127, but that is 
likely due to the addition of TPP and PLGA.  
Varying the ratio of PLGA to PF127-TPP while keeping the overall polymer 
concentration constant at 10mg/ml required using less PLGA for the 1:3 and 1:1.5 ratios (5mg 
and 8mg, respectively), as opposed to using 10mg for the 1:1 ratio. Reducing the amount of 
PLGA from 10 to 8mg, and from 8 to 5mg, resulted in larger and less homogeneous 
nanoparticles each time (260.50±5.0nm with PDI 0.219 and 360.90±13nm with PDI 0.278 for 
1:1.5 and 1:3, respectively). Including less of the very hydrophobic PLGA in the organic phase 
meant that the overall hydrophobicity of that phase was decreased, which gave rise to larger, less 
homogeneous nanoparticles. 
3.2 Hyaluronic acid modification 
Hyaluronic acid modification was confirmed via zeta potential measurements taken with 
DLS (Figure 3). Plain PF127 nanoparticles have a negative surface charge (-48.17±2.16mV), but 
once PF127 had been modified with TPP, nanoparticles had a positive surface charge 
(38.21±7.57mV). This shift from negative to positive surface charges makes sense, as TPP is a 
highly cationic molecule. HA on the other hand, is anionic. As such, modification of HA onto 
PPP-T nanoparticles took place via simple electrostatic interactions between TPP and HA. The 
resulting surface charge of nanoparticles (PPP-TH) was thus negative once again (-35.54±3mV). 
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 Modification with HA is in theory important in more than just cellular targeting via CD44 
receptors. The electrostatic interactions between HA and TPP are stable at a normal body pH 
(~7.4). However, the pH in tumor microenvironments is more acidic than normal (~6.0) mostly 
due to hypoxic conditions. Further, the pH of cell transport vesicles such as endosomes and 
lysosomes is even lower (~5.0). As the pH of the solution that PPP-TH nanoparticles are in 
decreases, it is thought that the electrostatic interactions between TPP and HA are disrupted. 
Eventually TPP and HA will dissociate, and we think that this dissociation will disrupt the 
stability of the entire nanoparticle, resulting in release of the payload inside the cell.  
3.3 Encapsulation efficiency of Ps-Cl 
 First, to confirm that PPP-T nanoparticles were encapsulating Ps-Cl, the absorbance of 
loaded PPP-T nanoparticles was compared to free Ps-Cl at 405nm. Both samples had the same 
peak, confirming encapsulation. With this confirmed, the encapsulation efficiency of Ps-Cl 
within PPP-T nanoparticles was investigated and found to be 73.5±3.4%. This is higher than 
values that were found for typical nanoprecipitation methods, which tend to fall within 45-65% 
Figure 3: Surface charges of nanoparticles at various stages of modification. TPP modification caused the surface 
charge of PF127 nanoparticles to become positive, while HA modification was confirmed via a negative surface 
charge. 
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encapsulation. This could be for a number of reasons. First, Ps-Cl is an exceptionally 
hydrophobic drug, which automatically makes it an ideal candidate for nanoprecipitation 
methods. Second, this method provides a much more uniform process for nanoparticle formation 
than traditional nanoprecipitation. The co-axial streams allow for homogeneous mixing between 
the water and oil phases before they even reach the flask, whereas in traditional methods the oil 
phase is added directly into the flask and mixed under turbulent, heterogeneous conditions. 
Either of these could account for the high encapsulation efficiency of Ps-Cl. While a direct 
comparison was not made between encapsulation efficiencies using the method described here 
and a traditional nanoprecipitation method, we still believe that the novel method would result in 
higher encapsulation of Ps-Cl.  
3.4 Encapsulating Lonidamine and Doxorubicin 
 Nanoparticles encapsulating Lon and Dox formed using this novel method did not see as 
promising results as those encapsulating Ps-Cl (Figure 4). PPL-T nanoparticles had a mean 
diameter of 253.51±19.0nm and a PDI of 0.434. Further, the encapsulation efficiency of Lon was 
only 36.3±5.2%. Oddly, the surface charge of PPL-T nanoparticles was measured to be -41.63 
±2.1mV. The high PDI and low encapsulation efficiency could be due to Lon being somewhat 
hydrophilic. Its more hydrophilic nature would allow for more interactions with water and thus 
less of a chance of being encapsulated. Additionally, if it was encapsulated it might bring water 
molecules along with it into the core of nanoparticles, effecting their size and homogeneity. The 
negative surface charge of PPL-T nanoparticles is harder to explain. It may also have something 
to do with the hydrophilicity of Lon and the subsequent lack of homogeneity, but we are 
ultimately unsure as to why this was observed. 
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While the PDI of PPD-T nanoparticles was very low (0.003), the mean diameter was 
slightly larger than PPP-T nanoparticles at 188.66±3.0nm. The encapsulation of Dox was much 
lower than Ps-Cl at 21.9±15.1%. The surface charge of PPD-T particles was positive as expected 
at 41.12±21.8mV, although less homogeneous than PPL-T nanoparticles, as is indicated by the 
high standard deviation and secondary peak at 23mV. While free Dox is a hydrophobic drug, the 
method used to obtain free Dox may have been inefficient and thus affected the encapsulation 
efficiency and zeta potential. As stated in the methods section, the stock Dox powder was a 
hydrochloride salt, making it soluble in water. To rid the Dox of the hydrochloride group, it was 
dissolved in methanol and TEA. This freeing method may not have been totally efficient, leaving 
some hydrophilic Dox in solution. In addition, methanol is fairly miscible in water. 
Nanoprecipitation methods take advantage of the hydrophobic and immiscible nature of the 
a) 
Figure 4: Size and surface charge of PPL-T and PPD-T nanoparticles. a) DLS and TEM both show larger PPL-T nanoparticles 
with a less homogeneous size distribution than PPP-T. Oddly, the surface charge of PPL-T particles was strongly negative. b) 
PPD-T nanoparticles were very homogeneous in both DLS and TEM measurements, although slightly larger than PPP-T 
nanoparticles. Surface charge of PPD-T particles was positive as expected, but not as homogeneous as PPP-T. 
b) 
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organic phase, so having hydrophilic Dox and a miscible organic phase could have effected 
subsequent nanoparticle formation and encapsulation.  
3.5 Mitochondrial targeting 
 While it would have been ideal to confirm the mitochondrial targeting of both TPP 
modified nanoparticles and Ps-Cl, it was only possible to determine the former. Ps-Cl is an 
inherently photoluminescent molecule with an emission peak around 650nm. At the time of this 
study, there was no confocal microscopes available with that particular wavelength of light, so 
Ps-Cl could not be detected. Instead, we used PPD-T nanoparticles and took advantage of the 
photoluminescent properties of Dox to test mitochondrial targeting of TPP modified 
nanoparticles in vitro (Figure 5). 
Figure 5: Confocal images showing mitochondrial targeting of TPP modified nanoparticles. An orange color seen in the merge 
indicates an overlap of Dox and Mito Deep Red, confirming targeting. This color is more prevalent in the PPD-T group than the 
PPD and Free Dox groups. 
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 After incubating 231 cells with either free Dox, PPD (untargeted) nanoparticles, or PPD-
T (targeted) nanoparticles for 4 hours, confocal images confirmed the targeting capabilities of 
TPP modified nanoparticles in vitro. Free Dox – once in cells – gathers in the nucleus, so it was 
expected to see an overlap of free Dox and DAPI, but not with Mito Deep Red. Dox 
encapsulated in nanoparticles however, would most likely not be able to get in the cell nuclei 
thus remaining in the cytosol. Cells treated with untargeted PPD nanoparticles did show Dox in 
the cytosol and not the nuclei, but there was not a good overlap with mitochondria. Rather, there 
appeared to be individual red and green areas in the overlap with only minimal orange areas. 
However, cells treated with targeted PPD-T nanoparticles showed an excellent overlap between 
Dox and mitochondria, as was indicated by the orange color seen in most cells in the overlapped 
images. The fluorescent intensity of Dox also appears to be stronger in cells treated with PPD-T 
particles than PPD particles. The addition of highly cationic TPP to nanoparticles and overall 
positive surface charge makes cellular uptake much easier, which accounts for this observation. 
Thus, while confirming mitochondrial targeting of both Ps-Cl and TPP would have been 
desirable, it was at least confirmed for TPP modified nanoparticles. 
Chapter 5: Conclusions 
 
 In this study, we aimed to create small, homogeneous nanoparticles capable of 
encapsulating therapeutic drugs using a somewhat novel nanoprecipitation method. Additionally, 
we sought to modify the surfaces of these nanoparticles with TPP, a mitochondrial targeting 
moiety, and HA, a ligand for the CD44 cell surface receptor overexpressed in many types of 
cancers. We found that with this double lumen needle method, a polymer concentration of 
10mg/ml, infusion rates of 20ml/hr for water and 4ml/hr for oil, and a 1:1 ratio of PLGA to 
PF127-TPP created the smallest, most homogeneous nanoparticles. Nanoparticles encapsulating 
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Ps-Cl using this method were 168.48±6.3nm with a PDI of 0.05. The encapsulation efficiency of 
Ps-Cl was also high, at 73.5±3.4%. While a direct comparison was not made between this 
method and a traditional nanoprecipitation method, these results still indicate that the method 
described here may be superior to others. Using a double lumen needle for nanoprecipitation can 
result in nanoparticle homogeneity and encapsulation efficiencies similar to those seen in 
microfluidics studies. However, this method is not as complicated, time consuming, or expensive 
as microfluidics approaches, giving it an advantage.  
 Successful modification with both TPP and HA was confirmed via zeta potential 
measurements. The addition of TPP resulted in an overall positive surface charge of 
38.21±7.57mV for nanoparticles, while HA addition resulted in an overall negative surface 
charge of -35.54±3.0mV. The use of mitochondrial targeting agents (i.e. TPP and Ps-Cl) gives 
this nanoparticle platform the potential to treat drug resistant populations of both typical cancer 
cells and CSCs. Further, the addition of HA to nanoparticles gives them the ability to target 
cancer cells that overexpress the CD44 cell surface receptor, which is a common phenotype. The 
electrostatic interactions between TPP and HA may also be a potential mechanism for drug 
release once the nanoparticles are internalized in cells. Despite this phenomenon not being 
directly examined in this study, it would be straightforward to analyze in future experiments.  
Within this study, only the targeting capabilities of TPP modified particles without HA 
were examined. Using PPD-T nanoparticles that had a lower encapsulation efficiency than PPP-
T particles, TPP targeting was confirmed via confocal microscopy images. Future studies would 
seek to measure the targeting capabilities of Ps-Cl and HA modified nanoparticles in both 2D 
and 3D cultures in vitro. We would also seek to improve the encapsulation efficiencies of Lon, 
Dox, and possibly other drugs, as well as consider this method for being able to encapsulate 
18 
 
multiple therapeutic agents at a time. Additionally, we would want to test the efficacy of PPP-TH 
nanoparticles in a stem cell enriched 3D environment in vitro in killing malignant cell 
populations. After this, in vivo studies might be conducted with PPP-TH nanoparticles to 
examine how effective they are in a true biological system and how they are metabolized within 
the body. Despite the limitations and drawbacks of this study, it was able to show that this 
method is viable for synthesizing nanoparticles capable of targeting drug resistant cells and CSC 
sub-populations, and it an important step in treating cancer in a cheap, efficient, and complete 
manner.     
19 
 
References 
 
1. Liu, Can, K. Kelnar, B. Liu, X. Chen, T. Calhoun-Davis, H. Li, L, Patrawala, H. Yan, C. 
Jeter, S. Honorio, J.F. Wiggins, A.G. Bader, R. Fagin, D. Brown, and D.G. Tang. "The 
microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing 
CD44." Nature Medicine 17.2 (2011): 211-216. 
2. Jordan, Craig T., M.L. Guzman, and M. Noble. "Cancer Stem Cells." The New England 
Journal of Medicine 355.12 (2006): 1253-1261. 
3. Patrawala, L, T. Calhoun, R. Schneider-Broussard, H. Li, B. Bhatia, S. Tang, J.G. Reilly, D. 
Chanrda, J. Zhou, K. Coghlan, and D.G. Tang. “Highly purified CD44+ prostate cancer cells 
from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells.” 
Oncogene 25.12 (2006): 1696-1708. 
4. Fasehee, Hamidreza, R. Dinarvand, A. Ghavamzadeg, M. Esfandyari-Manesh, H. Moradian, 
S. Faghihi, and S.H. Ghaffari. “Delivery of disulfiram into breast cancer cells using folate-
receptor-targeted PLGA-PEG nanoparticles: in vitro and in vivo investigations.” J. of 
Nanobiotech 14.32 (2016). 
5. Yi, Huqiang, L. Liu, N. Sheng, P. Li, H. Pan, L. Cai, and Y. Ma. “Synergistic therapy of 
doxorubicin and miR-129-5p with self-crosslinked bioreducible polypeptide nanoparticles 
reverses multidrug resistance is cancer cells.” Biomacromolecules 17.5 (2016): 1737-1747. 
6. Wang, Hai, P. Agarwal, S. Zhao, R.X. Xu, J. Yu, X. Lu, and X. He. “Hyaluronic acid-
decorated dual responsive nanoparticles of Pluronic F127, PLGA, and chitosan for targeted 
co-delivery of doxorubicin and irinotecan to eliminate cancer stem-like cells.” Biomaterials 
72 (2015): 74-89. 
7. Auzenne, Edmond, S.C. Ghosh, M. Khodadadian, B. Rivera, D. Farquhar, R.E. Price, M. 
Ravoori, V. Kundra, R.S. Freedman, and J. Klostergaard. "Hyaluronic Acid-Paclitaxel: 
Antitumor Efficacy against CD44(+) Human Ovarian Carcinoma Xenografts." Neoplasia 9.6 
(2007): 479-486. 
8. Marrache, Sean, R.K. Pathak, and S. Dhar. “Formulation and optimization of mitochondria-
targeted polymeric nanoparticles.” Mito Med Vol II, Manipulating Mito Func. 1265 (2015): 
103-112. 
9. Fulda, Simone, L. Galluzzi, and G. Kroemer. “Targeting mitochondria for cancer therapy.” 
Nature Reviews Drug Discovery 9 (2010): 447-464. 
10. Karnik, Rohit, F. Gu, P. Basto, C. Cannizzaro, L. Dean, W. Kyei-Manu, R. Langer, and O.C. 
Farokhzad. “Microfluidic platform for controlled synthesis of polymeric nanoparticles.” 
Nano letters 8.9 (2008): 2906-12. 
11. Rhee, Minsoung, P.M. Valencia, M.I. Rodriguez, R. Langer, O.C. Farokhzad, and R. Karnik. 
“Synthesis of size-tunable polymeric nanoparticles enabled by 3D hydrodynamic flow 
focusing in single-layer microchannels.” Adv. Mater 23.12 (2011): H79-83. 
12. “Cancer Statistics.” National Cancer Institute. N.N., 22 Mar. 2017. Web 
<https://www.cancer.gov/about-cancer/understanding/statistics>. 
13. Xu, Jiangsheng, F. Zeng, H. Wu, C. Hu, and S. Wu. “Enhanced photodynamic efficiency 
achieved via a dual-targeted strategy based on photosensitizer/micelle structure.” 
Biomacromolecules 15 (2014): 4249-49. 
